Le JDB : Gilles Avenard (Acticor Biotech), Frédéric Gomez (Pharmium Securities)

from Le Journal des Biotechs · host BOURSORAMA

Dans ce numéro du journal des biotechs, Frédéric Gomez, analyste chez Pharmium Securities revient sur les dossiers chauds du moment : Valneva, Abionyx et Sensorion.L'entretien est consacré à Gilles Avenard, cofondateur et directeur général d'Acticor biotech qui développe un candidat-médicament pour le traitement de la phase aiguë de l’accident vasculaire cérébral ischémique et d’autres urgences cardiovasculaires.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Episode metadata supplied by the publisher feed · Published Oct 26, 2021

Embed this episode

Attribution link and audio player

NOW PLAYING

Le JDB : Gilles Avenard (Acticor Biotech), Frédéric Gomez (Pharmium Securities)

0:00 26:54

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Le Journal des Biotechs?

This episode is 26 minutes long.

When was this Le Journal des Biotechs episode published?

This episode was published on October 26, 2021.

Can I download this Le Journal des Biotechs episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!